natgillin/translations-raw huggingface dataset:
55 The Commission awarded a grant in 2018 to the Managing Entity of the Combacte projects to develop a business model for a new clinical trials network (ECRAID - plan), to merge the existing ŇCombacteÓ network with a clinical trials network developed for emerging infectious diseases. 
55 r 2018 beviljade kommissionen ett bidrag till Combacte-projektens frvaltningsenhet fr att den skulle ta fram en affrsmodell fr ett nytt ntverk fr kliniska prvningar (ECRAID-Plan), dr det befintliga Combacte-ntverket skulle integreras med ett ntverk fr kliniska prvningar avsett fr nya infektionssjukdomar.
ECRAID - plan is scheduled to start in 2021. 
ECRAID-Plan berknas inledas under 2021.
At the time of our audit there was no agreed process to maintain the infrastructures developed under Combacte. 
Nr vi genomfrde revisionen fanns det ingen verenskommen process fr att bibehlla den infrastruktur som tagits fram inom ramen fr Combacte.
56 In the EU One Health Action Plan on AMR, the Commission set the objective to support SMEs in their research and development efforts. 
56 I EU:s One Health-handlingsplan mot antimikrobiell resistens faststllde kommissionen mlet att stdja sm och medelstora fretag i deras forsknings-och utvecklingsinsatser.
The role of SMEŐs in the discovery of antimicrobials is increasing, particularly given the withdrawal of large pharmaceutical companies from such research (see paragraph 07). 
Sm och medelstora fretag fr en allt viktigare roll nr det gller upptckt av nya antimikrobiella medel, i synnerhet med tanke p att stora lkemedelsfretag drar sig tillbaka frn sdan forskning (se punkt 07).
Only about 5 % of funding from the ND4BB programme had been used for SMEs, mostly under the Enable project for drug discovery. 
Enbart omkring 5 % av finansieringen frn ND4BB-programmet hade anvnts till sm och medelstora fretag, frmst inom ramen fr Enable-projektet fr lkemedelsupptckt.
57 The EU One Health Action Plan provides a strategy for the CommissionŐs support and research activities. 
57 I EU:s One Health-handlingsplan anges en strategi fr kommissionens std-och forskningsverksamheter.
It includes planned actions to improve knowledge on detection, infection control and surveillance; develop new therapeutics and alternatives; and develop new preventive vaccines. 
Den inbegriper planerade tgrder fr att ka kunskaperna om detektion, infektionsbekmpning och vervakning, utveckla nya terapier och alternativ samt utveckla nya preventiva vacciner.
However the Action Plan does not address all of the specific challenges for AMR research, notably: Ń the long timelines and challenges involved in the discovery and development of new antibiotics; 33 Ń how to integrate long term research priorities and sustain activities across programming periods; Ń methods for working with all relevant stakeholders (academics, SMEs, pharmaceutical industries, international funding and coordination initiatives). 
Men handlingsplanen tar inte upp alla specifika utmaningar fr forskningen om antimikrobiell resistens, ssom Ń de lnga tidsramarna och utmaningarna fr att upptcka och utveckla ny antibiotika, Ń hur man ska integrera lngsiktiga forskningsprioriteringar och upprtthlla verksamheter under olika programperioder, Ń metoder fr att arbeta med samtliga relevanta berrda parter (akademiker, sm och medelstora fretag, lkemedelsindustrier, internationell finansiering och samordningsinitiativ).
Commission initiatives have not yet resolved the market failures in antimicrobial research and development 58 Pharmaceutical companies have decided to withdraw from the market of certain Member States some antimicrobials that continue to work39, such as a first-line treatment option for community-acquired pneumonia, and a recommended treatment for certain urinary tract infections. 
35 Kommissionens initiativ har nnu inte lst marknadsmisslyckandena inom antimikrobiell forskning och utveckling 58 Lkemedelsfretag har beslutat att i vissa medlemsstater dra tillbaka ngra nnu verksamma antimikrobiella medel39 frn marknaden, ssom ett frsta linjens behandlingsalternativ fr samhllsfrvrvad pneumoni och en rekommenderad behandling fr vissa urinvgsinfektioner.
The Commission does not have an explicit mandate to propose initiatives to avoid or slow down the withdrawal of existing antimicrobials from the market. 
Kommissionen har inte ngon uttalad befogenhet att fresl initiativ fr att frhindra eller frdrja att befintliga antimikrobiella medel dras tillbaka frn marknaden.
59 In its 2017 EU One Health Action Plan on antimicrobial resistance, the Commission had tasked itself with supporting research into the development of new economic models to support the development of new antimicrobials. 
59 I One Health-handlingsplanen mot antimikrobiell resistens frn 2017 gav kommissionen sig sjlv i uppdrag att stdja forskning om nya ekonomiska modeller fr att stdja utvecklingen av nya antimikrobiella medel.
60 We found that despite the general withdrawal of pharmaceutical industries from antimicrobial research, JU IMI together with its partners was overall able to maintain the expected level of public-private collaboration in the ND4BB programme (see Table 2). 
60 Trots att lkemedelsindustrin generellt sett dragit sig tillbaka frn den antimikrobiella forskningen konstaterade vi att det gemensamma fretaget IMI tillsammans med dess partner i allmnhet lyckades upprtthlla den frvntade nivn p det offentlig-privata samarbetet inom ramen fr ND4BB-programmet (se tabell 2).
While this is encouraging, there are concerns about the insufficient commercial incentives for pharmaceutical companies to invest in this field. 
Det r lovande, men det finns viss oro fr att de kommersiella incitamenten inte r tillrckliga fr att lkemedelsfretag ska investera p detta omrde.
61 The Drive-AB project produced a report in March 2018 making recommendations for strengthening the investment climate and pipeline for new antimicrobials. 
61 Drive-AB-projektet framstllde en rapport i mars 2018 dr det lmnades rekommendationer fr att strka investeringsklimatet och utvecklingen av nya antimikrobiella medel.
The report confirmed that the market for developing new antimicrobials was in general not commercially attractive. 
Rapporten bekrftade att marknaden fr att utveckla nya antimikrobiella medel generellt sett inte var kommersiellt attraktiv.
It explained how push incentives such as grants may pay for the costs of R&D but did not improve the attractiveness of the overall market. 
Den frklarade hur push-incitament, ssom bidrag, kunde tcka kostnaderna fr forskning och utveckling men inte gjorde marknaden som helhet mer attraktiv.
The report concluded that pull mechanisms were needed. 
I rapporten drogs slutsatsen att det krvs pull-mekanismer.
The Commission has disseminated the results of the Drive-AB study to Member States, and in consultation with international partners (see paragraph 47) was considering next steps to boost development of new 39 See ŇTackling DrugĐResistant Infections Globally: Final report and recommendationsÓ, 2016, by the UK Review on AMR; Unavailability of old antibiotics threatens effective treatments for common bacterial infectionsÓ, Lancet Volume 18 2018. 
Det uppskattades att det skulle krvas omkring en miljard euro i pull-mekanismer fr att gra det mjligt att fra ut en helt ny antibiotika p marknaden. Kommissionen har spridit resultaten frn Drive-AB-studien till medlemsstaterna och i samrd med internationella partner (se punkt 47) vervgt vad som br gras hrnst fr att frmja utvecklingen av nya antimikrobiella medel.
By the time of our audit the Commission had not decided on specific initiatives to promote pull mechanisms. 
Nr vi genomfrde revisionen hade kommissionen inte beslutat om specifika initiativ fr att frmja pull-mekanismer.
Conclusions and recommendations 62 Antimicrobial resistance (AMR) happens when microbes develop resistance against medicines that previously worked. 
36 Slutsatser och rekommendationer 62 Antimikrobiell resistens uppstr nr mikrober utvecklar resistens mot lkemedel som tidigare fungerade.
It is a serious and growing threat to global and European health. 
Det r ett allvarligt och vxande hot mot global och europeisk hlsa.
An estimated 33 000 people already die each year in the EU / EEA from infections caused by drug resistant bacteria, leading to additional costs of Ű1.5 billion. 
Uppskattningsvis dr redan nu 33 000 personer varje r i EU/EES p grund av infektioner som orsakas av lkemedelsresistenta bakterier. Det fr med sig extra kostnader p 1,5 miljarder euro.
The EU follows the ŇOne HealthÓ approach to AMR, with an integrated approach to human health, animal health and the environment. 63 Human health is a Member State competence. 
EU tillmpar en ÓOne HealthÓ-modell fr att hantera antimikrobiell resistens, med en integrerad strategi fr mnniskors hlsa, djurhlsa och miljn. 63 Mnniskors hlsa hr till medlemsstaternas befogenheter.
The CommissionŐs role is to complement and support Member StatesŐ actions. 
Kommissionen har som roll att komplettera och stdja medlemsstaternas tgrder.
There are EU rules on monitoring the consumption of antimicrobials and on the surveillance of resistant infections. 
Det finns EU-regler om vervakning av frbrukningen av antimikrobiella medel och om vervakning av resistenta infektioner.
The CommissionŐs mandate for action is more clearly defined for veterinary and food related issues (paragraphs 14 to 16). 
Kommissionens mandat att vidta tgrder r definierat p ett tydligare stt nr det gller veterinra och livsmedelsrelaterade frgor (punkterna 14Đ 16).
64 We examined whether the Commission and relevant EU agencies managed well key activities and resources to support Member States and EU funded research aimed at fighting AMR (paragraphs 18 and 19). 
64 Vi underskte om kommissionen och berrda EU-organ frvaltade viktiga verksamheter och resurser p ett bra stt fr att stdja medlemsstaternas arbete och EU-finansierad forskning fr att bekmpa antimikrobiell resistens (punkterna 18Đ19).
65 We conclude that the activities of the Commission and agencies have led to some progress, for example, in veterinary and food related issues. 
65 Vi drar slutsatsen att kommissionens och byrernas tgrder har lett till vissa framsteg, till exempel nr det gller veterinra och livsmedelsrelaterade frgor.
However, there is little evidence to date that the health burden of AMR has been reduced in the European Union. 
Det finns dock i dagslget f bevis p att hlsobrdan till fljd av antimikrobiell resistens har minskats inom Europeiska unionen.
66 We found that the Commission and ECDC support to strengthen Member StatesŐ One Health approach to AMR, while appreciated by the Member States and having the potential to provide a positive impact, has not yet delivered demonstrable results in reducing AMR. 
66 Vi konstaterade att kommissionens och ECDC:s std till att strka medlemsstaternas One Health-modell fr antimikrobiell resistens uppskattas av medlemsstaterna och har potential att ge positiva effekter, men att det nnu inte har lett till pvisbara resultat i form av minskad antimikrobiell resistens.
We found that the EU funded Joint Action on antimicrobial resistance (JAMRAI) facilitated cooperation between Member States but faced challenges, particularly to the sustainable implementation of its results in the Member States (paragraph 23 and 24). 
Vi konstaterade att den EU-finansierade gemensamma tgrden om antimikrobiell resistens (JAMRAI) underlttade samarbetet mellan medlemsstaterna, men det visade sig vara svrt att genomfra resultaten p ett hllbart stt i medlemsstaterna (punkterna 23 och 24).
An EU funded and OECD led project demonstrated that there was a range of relatively simple, cheap and cost effective options (antibiotic stewardship programmes, infection prevention and control measures, media campaigns and the use of rapid diagnostic tests) to reduce AMR in hospitals and other healthcare settings. 
Ett EU-finansierat och OECD-lett projekt visade att det fanns en rad relativt enkla, billiga och kostnadseffektiva alternativ (program fr strategier fr antimikrobiell lkemedelsbehandling, tgrder fr att frebygga och bekmpa infektioner, mediekampanjer och anvndning av snabba diagnostiska tester) fr att minska antimikrobiell resistens p sjukhus och i andra hlso-och sjukvrdsmiljer.
We consider that further synergies are available to support the fight against AMR by targeted, cost-effective investments co-financed with EU support in those Member States that need to take more incisive action (paragraphs 26 and 27). 
Vi anser att fler synergieffekter kan uppns i kampen mot antimikrobiell resistens genom riktade, 37
67 We found that overall, ECDC activities facilitate informed policy decisions (paragraphs 28 to 30). 
67 Vi konstaterade att ECDC:s verksamheter generellt sett frmjade vlgrundade politiska beslut (punkterna 28Đ30).
However a series of joint visits by the Commission and the ECDC to the Member States, which we found to be a useful tool to support their One Health National Action Plans, was progressing slowly due to the lower than anticipated demand from Member States (paragraph 29). 68 The Commission obtains information on AMR through various monitoring activities. 
Kommissionens och ECDC:s gemensamma besk i medlemsstaterna, som vi ansg var ett vrdefullt verktyg fr att stdja de nationella One Health-handlingsplanerna, genomfrdes dock i lngsam takt p grund av att efterfrgan frn medlemsstaterna var mindre n vad som frutsetts (punkt 29) 68 Kommissionen hmtar information om antimikrobiell resistens genom olika vervakningsverksamheter.
However, outcome indicators jointly developed by EU agencies were not consistently used by the Member States we visited, or by the Commission, to monitor progress (paragraphs 31 and 32). 
De utfallsindikatorer som tagits fram gemensamt av EU:s byrer anvndes dock inte konsekvent av de medlemsstater vi beskte, eller av kommissionen, fr att vervaka framstegen (punkterna 31 och 32).
EU surveillance data on healthcare associated infections, which are the primary source of infection by resistant bacteria in humans in Europe, is incomplete (paragraphs 33 to 35). 
EU:s vervakningsuppgifter om vrdrelaterade infektioner, vilka r den frmsta kllan till infektioner med resistenta bakterier hos mnniskor i Europa, r ofullstndiga (punkterna 33Đ35).
However, at the time of our audit there was insufficient knowledge on the occurrence and spread of AMR in the environment (paragraph 36). 
Vid tidpunkten fr vr revision var dock kunskaperna om frekomst och spridning av antimikrobiell resistens i miljn otillrckliga (punkt 36).
Recommendation 1 Đ Improving the EU response to AMR through better support to Member State national action plans The Commission, in consultation with the Member States should: (a) promote the results of the JAMRAI and OECD projects, and identify existing funding opportunities to better support the sustained implementation of Member StatesŐ AMR One Health policies; (b) use outcome indicators to assist Member States to measure their progress in fighting AMR; (c) when implementing its new approach to pharmaceuticals in the environment, assess the option of integrating the monitoring of AMR occurrence in the environment into existing environmental monitoring programmes. 
Rekommendation 1 Đ Frbttra EU:s tgrder mot antimikrobiell resistens genom att frbttra stdet till medlemsstaternas nationella handlingsplaner Kommissionen br i samrd med medlemsstaterna gra fljande: a) Uppmrksamma resultaten av JAMRAI-och OECD-projekt och identifiera befintliga finansieringsmjligheter fr att bttre stdja ett lngsiktigt genomfrande av medlemsstaternas One Health-strategier mot antimikrobiell resistens. b) Anvnda utfallsindikatorer fr att bist medlemsstaterna nr de mter framstegen i kampen mot antimikrobiell resistens. c) Bedma mjligheten att integrera vervakning av frekomsten av antimikrobiell resistens i miljn i befintliga program fr miljvervakning nr den nya strategin om lkemedel i miljn genomfrs.
Target implementation date: end 2021. 
Mldatum fr genomfrande: slutet av 2021.
69 The prudent use of veterinary antimicrobials is generally improving and certain Member States have made significant progress in curbing the sales of some antimicrobials for veterinary use. 
69 Anvndningen av antimikrobiella veterinrmedicinska lkemedel blir allmnt sett mer terhllsam och vissa medlemsstater har gjort betydande framsteg i frga om att begrnsa frsljningen av vissa antimikrobiella medel fr veterinr anvndning.
However, there are large differences between the lowest and highest consuming countries, and consumption of some antimicrobials is still too high (paragraphs 38 and 39). 
Det finns dock stora skillnader mellan de lnder dr frbrukningen r som lgst och som hgst, och frbrukningen av vissa antimikrobiella medel ligger fortfarande p en fr hg niv (punkterna 38 och 39).
The new EU rules for veterinary medicinal products and medicated feed addressed some known weaknesses in the framework 37 for reducing the consumption of antimicrobials and enhancing surveillance data. 
Genom de nya EU-reglerna om veterinrmedicinska produkter och foder som innehller lkemedel tgrdades vissa knda brister i ramen fr att minska frbrukningen av antimikrobiella medel och frbttra vervakningen.
However, some challenges remain, including the possible difficulty faced by Member States in collecting data. 
Vissa utmaningar kvarstr dock, bland annat att vissa medlemsstater kan ha svrigheter med att samla in uppgifter.
The future Common Agricultural Policy provides an opportunity to further strengthen the EU framework for dealing with AMR (paragraphs 40 to 43). 
Den framtida gemensamma jordbrukspolitiken utgr en mjlighet att ytterligare strka EU:s ram fr att hantera antimikrobiell resistens (punkterna 40Đ43).
70 The monitoring and reporting of the presence of resistant zoonotic and commensal bacteria in certain food of animal origin is the only AMR domain where the Commission has a clear inspection mandate. 
70 vervakningen och rapporteringen av frekomsten av resistenta zoonotiska och kommensala bakterier i vissa livsmedel av animaliskt ursprung r det enda omrde inom antimikrobiell resistens dr kommissionen har ett tydligt inspektionsmandat.
We found that this monitoring and reporting was generally well implemented, but there are still risk areas which merit consideration for the planned revision of the framework. 
Vi konstaterade att vervakningen och rapporteringen generellt sett genomfrdes p ett bra stt, men det finns fortfarande riskomrden som br beaktas infr den planerade versynen av ramen.
The Commission inspections led to improvements of Member State systems (paragraphs 44 and 45). 
Kommissionens inspektioner ledde till att medlemsstaternas system frbttrades (punkterna 44 och 45).
Recommendation 2 Đ Promoting better monitoring and the prudent use of veterinary antimicrobials The Commission, in consultation with the Member States should support Member States in developing systems (by defining minimum requirements and considering financial support) that comply with the data collection requirements of the new EU legislation on veterinary medicines. 
Rekommendation 2 Đ Frmja bttre vervakning och terhllsam anvndning av antimikrobiella veterinrmedicinska lkemedel Kommissionen br i samrd med medlemsstaterna stdja medlemsstaterna i utvecklingen av system (genom att definiera minimikrav och vervga ekonomiskt std) som verensstmmer med kraven fr uppgiftsinsamling i den nya EU-lagstiftningen om veterinrmedicinska lkemedel.
Target implementation date: end 2022. 
Mldatum fr genomfrande: slutet av 2022.
71 The Commission, with the EU budget, is one of the worldŐs largest single investors in AMR research and development. 
71 Kommissionen r, med EU-budgeten, en av vrldens strsta enskilda investerare i forskning och utveckling som rr antimikrobiell resistens.
The antimicrobials market lacks commercial incentives to develop new classes of antibiotics. 
Marknaden fr antimikrobiella medel saknar kommersiella incitament att utveckla nya antibiotikaklasser.
The Commission invested most of this budget in research to find and develop new treatments (via so called Ňpush-mechanismsÓ) due to the high costs for this type of activity and the reluctance of industry to invest. 
Kommissionen investerade strre delen av denna budget i forskning fr att upptcka och utveckla nya behandlingar (genom s.k. push-mekanismer) p grund av de hga kostnaderna fr den hr typen av verksamhet och industrins ovilja att investera.
This research is inherently complex and no breakthrough treatments have yet been brought to the market. 
Denna forskning r till sin natur komplex och hittills har inga 39 genombrottsbehandlingar slppts ut p marknaden.
We noted that the Commission had not comprehensively evaluated its investments in AMR research (paragraphs 07, 49 and 61). 
Vi noterade att kommissionen inte hade utvrderat investeringarna i forskning om antimikrobiell resistens p ett grundligt stt (punkterna 07, 49 och 61).
72 We found delays in certain AMR related projects funded via the public private partnership (i.e. the New Drugs for Bad Bugs programme) which the Commission deployed through JU IMI. 
72 Vi konstaterade att frseningar uppsttt i vissa projekt rrande antimikrobiell resistens med finansiering genom det offentlig-privata partnerskap (dvs. New Drugs for Bad Bugs-programmet) som kommissionen infrde genom det gemensamma fretaget IMI.
There are some interesting products in the research pipeline supported by this programme. 
Det finns en del intressanta produkter inom den pgende forskning som stds av detta program.
Valuable assets have already been created, aiming to speed up the successful development of new antimicrobials, and there are initiatives to sustain them. 
Vrdefulla tillgngar har redan skapats i syfte att snabba p framgngsrik utveckling av nya antimikrobiella medel, och det finns initiativ fr att upprtthlla dem.
address some of the specific challenges facing AMR research. For example, it does not cover how to better involve SMEs (which are key in identifying promising new compounds), and how to integrate long term research priorities and sustain activities across funding programing periods (paragraphs 50 to 57). 
Vi anser att kommissionens One Health-handlingsplan inte tar upp vissa av de specifika utmaningarna fr forskningen om antimikrobiell resistens Den sger till exempel ingenting om hur sm och medelstora fretag ska gras delaktiga p ett bttre stt (dessa fretag r centrala i frga om att identifiera lovande nya freningar) eller hur man ska integrera lngsiktiga forskningsprioriteringar och upprtthlla verksamheter under olika finansierings-och programperioder (punkterna 50 to 57).
73 Some antimicrobials that continue to work are withdrawn from the market. 
73 Vissa antimikrobiella medel som fortfarande fungerar dras tillbaka frn marknaden.
The Commission does not have an explicit mandate to propose initiatives to avoid or slow down this process (paragraph 58). 
Kommissionen har ingen uttalad befogenhet att fresl initiativ fr att frhindra eller frdrja den processen (punkt 58).
74 Although certain pharmaceutical companies have withdrawn from AMR research, the companies participating under the public private partnership generally maintained their overall commitments (paragraph 60). 
74 Vissa lkemedelsfretag har dragit sig tillbaka frn forskningen om antimikrobiell resistens, men de fretag som deltar i det offentlig-privata partnerskapet infriade generellt sett sina allmnna taganden (punkt 60).
75 In order to address the failure of the market to provide new antimicrobials, the Commission has explored economic incentive models (or Ňpull-mechanismsÓ) and liaised with stakeholders. 
75 Fr att hantera marknadens misslyckande nr det gller att tillhandahlla nya antimikrobiella medel har kommissionen underskt ekonomiska incitamentsmodeller (eller s.k. pull-mekanismer) och varit i kontakt med intressenter.